Abstract
Pharmacogenetics research involves the attempt to understand the hereditary basis for two individuals (with the possible exception of identical twins) responding differently to drugs or other foreign chemicals. These responses include therapeutic effects (e.g., control of seizures), but also undesirable effects (e.g., increased risk of drug toxicity or cancer). The experimental model to be examined in detail in this chapter represents principally a genetic difference in receptor concentration. Because of this defect, there are large genetic differences in the biotransformation and pharmacokinetics of certain drugs and other environmental pollutants, resulting in important variations in risk toward birth defects, drug toxicity, mutation, and certain types of cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Atlas SA, Zweier JL, Nebert DW (1980) Genetic differences in phenytoin pharmacokinetics. In vivo clearance and in vitro metabolism among inbred strains of mice. Dev Pharmacol Ther 1:281–304
Bigelow SW, Nebert DW (1982) The Ah regulatory gene product: survey of fifteen polycyclic aromatic compounds’ and fifteen benzo[a]pyrene metabolites’ capacity to bind to the cytosolic receptor. Toxicol Lett (Amst) 10:109–118
Filler R, Lew KJ (1981) Developmental onset of mixed-function oxidase activity in preim-plantation mouse embryos. Proc Nat Acad Sci USA 78:6991–6995
Galloway SM, Perry PE, Meneses J, Nebert DW, Pedersen RA (1980) Cultured mouse embryos metabolize benzo[a]pyrene during gestation: genetic differences detectable by sister chromatid exchange. Proc Nat Acad Sci USA 77:3524–3528
Ivanovic V, Weinstein IB (1981) Benzo[a]pyrene and other inducers of cytochrome Pr450 inhibit binding of epidermal growth factor (EGF) to cell surface receptors [Abstr] J Supramol Struct Cell Biochem [Suppl] 5:232
Jones KG, Sweeney GD (1980) Dependence of the porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo(p)dioxin upon inheritance of aryl hydrocarbon hydroxylase. Toxicol Appl Pharmacol 53:42–49
Knutson JC, Poland A (1980) Keratinization of mouse teratoma cell line XB produced by 2,3,7,8-tetrachlorodibenzo-P-dioxin: an in vitro model of toxicity. Cell 22:27–36
Kouri RE, McKinney D, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer-Analysis in cryopreserved lymphocytes. Cancer Res (in press)
Kutt H (1971) Biochemical and genetic factors regulating dilantin metabolism in man. Ann NY Acad Sci 179:705–722
Lambert GH, Nebert DW (1977) Genetically mediated induction of drug-metabolizing enzymes associated with congenital defects in the mouse. Teratology 16:147–153
Lang MA, Nebert DW (1981) Structural gene products of the Ah locus. Evidence for many unique P-450-mediated monooxygenase activities reconstituted from 3-methylcholan-threne-treated C57BL/6N mouse liver microsomes. J Biol Chem 256:12,058–12,067
Lang MA, Gielen JE, Nebert DW (1981) Genetic evidence for many unique liver microsomal P-450-mediated monooxygenase activities in heterogeneic stock mice. J Biol Chem 256:12,068–12,075
Latt SA, Allen JW, Stetten G (1977) In vitro and in vivo analyses of chromosome structure, replication, and repair using BrdU-33258 Hoechst techniques. In: Brinkley BR, Porter KR (eds) Proceedings of the first international congress on cell biology. Rockefeller University Press, New York, pp 520–527
Nebert DW (1973) Use of fetal cell culture as an experimental system for predicting drug metabolism in the intact animal. Clin Pharmacol Ther 14:693–699
Nebert DW (1979) Multiple forms of inducible drug-metabolizing enzymes. A reasonable mechanism by which any organism can cope with adversity. Mol Cell Biochem 27:27–46
Nebert DW (1980) The Ah locus. A gene with possible importance in cancer predictability. Arch Toxicol [Suppl] 3:195–207
Nebert DW (1981) Birth defects and the potential role of genetic differences in drug metabolism. In: Bloom AD, James LS (eds) Birth defects: original article series, vol XVII. AR Liss, New York, pp. 51–70
Nebert DW, Jensen NM (1979) Genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. In: Fasman GD (ed) CRC critical reviews in biochemistry, vol 6. CRC Press, Cleveland, pp 410–437
Nebert DW, Shum S, (1980) Reply to the letter of Doctors Shepard and Fantel. Teratology 22:349–350
Nebert DW, Levitt RC, Jensen NM, Lambert GH, Felton JS (1977) Birth defects and aplastic anemia: differences in polycyclic hydrocarbon toxicity associated with the Ah locus. Arch Toxicol 39:109–132
Nebert DW, Eisen HJ, Negishi M, Lang MA, Hjelmeland LM, Okey AB (1981) Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities. Annu Rev Pharmacol Toxicol 21:431–462
Nebert DW, Negishi M, Lang MA, Hjelmeland LM, Eisen HJ (1982) The Ah locus, a multigene family necessary for survival in a chemically adverse environment: comparison with the immune system. Adv Genet 21:1–52
Negishi M, Nebert DW (1979) Structural gene products of the Ah locus. Genetic and immunochemical evidence for two forms of mouse liver cytochrome P-450 induced by 3-methylcholanthrene. J Biol Chem 254:11,015–11023
Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378
Poland A, Glover E (1980) 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Segregation of toxicity with the Ah locus. Mol Pharmacol 17:86–94
Shum S, Jensen NM, Nebert DW (1979) The Ah locus: In utero toxicity and teratogenesis associated with genetic difference in benzo[a]pyrene metabolism. Teratology 20:365–376
Sloan TP, Idle JR, Smith RL (1981) Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 29:493–497
Smith DW (ed) (1976) Recognizable patterns of human malformation, 2nd edn. WB Saunders, Philadelphia
Vasko MR, Bell RD, Daly DD, Pippenges CE (1980) Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 27:96–103
Williams RT (ed) (1959) Detoxication mechanisms, 2nd edn. Wiley & Sons, New York
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Nebert, D.W. (1983). Genetic Differences in Drug Metabolism: Proposed Relationship to Human Birth Defects. In: Johnson, E.M., Kochhar, D.M. (eds) Teratogenesis and Reproductive Toxicology. Handbook of Experimental Pharmacology, vol 65. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81919-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-81919-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81921-6
Online ISBN: 978-3-642-81919-3
eBook Packages: Springer Book Archive